Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
Public ClinicalTrials.gov record NCT00477594. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Extension Study to Assess the Long-term Safety and Efficacy of Mipomersen in Subjects With Familial Hypercholesterolemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and efficacy of extended dosing of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008) clinical drug trials.
Study identification
- NCT ID
- NCT00477594
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 21 participants
Conditions and interventions
Conditions
- Lipid Metabolism, Inborn Errors
- Hypercholesterolemia, Autosomal Dominant
- Hyperlipidemias
- Metabolic Diseases
- Hyperlipoproteinemia Type II
- Metabolism, Inborn Errors
- Genetic Diseases, Inborn
- Infant, Newborn, Diseases
- Metabolic Disorder
- Congenital Abnormalities
- Hypercholesterolemia
- Hyperlipoproteinemias
- Dyslipidemias
- Lipid Metabolism Disorders
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2007 (Type not available)
- Primary completion
- Mar 2011 (Actual)
- Completion
- Jul 2011 (Actual)
- Last update posted
- Sep 9, 2016
2007 – 2011
United States locations
- U.S. sites
- 5
- U.S. states
- 3
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Chicago | Illinois | 60654 | — |
| Not listed | Auburn | Maine | 04210 | — |
| Not listed | Biddeford | Maine | 04005 | — |
| Not listed | Scarborough | Maine | 04074 | — |
| Not listed | Cincinnati | Ohio | 45212 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00477594, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 9, 2016 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00477594 live on ClinicalTrials.gov.